Maintaining Postmenopausal Health

A continuing education activity 
supported through an educational grant 
from 
Eli Lilly & Company

A number of figures and tables are displayed on this page.  Please allow time for them to download.

 


Table 3-1: Selected Types of Estrogens 
and Their Clinical Uses
  Conjugated estrogens Commonly used to treat menopausal and postmenopausal symptoms as well as long-term consequences of estrogen deficiency. May be used alone (eg, Premarin®) or in combination with progestins (eg, Premphase®, Prempro®).
  Estrogen esters Synthetic agents derived chemically from estradiol or estrone.
  17-a-ethinyl estradiol Main estrogens in the oral contraceptive pill (eg, ethinyl estradiol, mestranol).
  Dienestrol Used topically to treat symptoms of vaginal atrophy

After reading Table 3-1, return to text 

 

Table 3-2
Estrogen Products Approved 
for Prevention of Bone Loss28,33
Generic Name Brand Name Minimum Daily Dose to prevent postmenopausal bone loss
Conjugated estrogens Premarin® Premphase® * Prempro™ * 0.625 mg
Esterified estrogens Estratab®
Menest®		 0.3 mg
Estradiol Estrace® 0.5 mg
Estradiol transdermal system Alora®
Climara®
Estraderm®
Vivelle®		 0.05 mg/day patch (applied twice weekly)
Estropipate Ogen®
Ortho-EST®		 0.625 mg
* conjugated estrogens + medroxyprogesterone acetate

After reading Table 3-2, return to text

 

Figure 3-2
Effects of Postmenopausal Estrogen Replacement on Blood Lipids

Figure 3-2

After reading Figure 3-2, return to text

 

Figure 4-1
Changes in Bone Mineral Density in Postmenopausal Women
Taking Alendronate (Fosamax) 10 mg/day for 3 years66

Figure 4-1

After reading Figure 4-1, return to text

 

Figure 5-1
Changes in Markers of Bone Turnover in Women
Taking Raloxifene (60 mg/day and 120 mg/day)

Figure 5-1

After reading Figure 5-1, return to text

 

 

Figure 5-2
Changes in Bone Mineral Density in Postmenopausal Women Taking Raloxifene (Evista) 60 mg/day or 120 mg/day for 6 months 85

Figure 5-2

After reading Figure 5-2, return to text

 

Figure 5-3
Reduction in New Vertebral Fractures Among 6.828 Women
Who Completed the Study 85

Figure 5-3

Women did or did not have vertebral fracture at the beginning of study.  RR indicates relative risk;  CI, confidence interval.

After reading Figure 5-3, return to text